Evidence map›Paper›PMID 15133631›Full record

ArticleCancer immunology, immunotherapy : CII2004

Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M.

Dirk Nagorsen, Catherine Servis, Nicole Lévy, Maurizio Provenzano, Mark E Dudley, Francesco M Marincola, Frédéric Lévy

Open access · greenAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Dirk NagorsenImmunogenetics Section, Department of Transfusion Medicine, NIH Clinical Center, 10 Center Drive, Bethesda, MD 20892-1502, USA.
Catherine Servis
Nicole Lévy
Maurizio Provenzano
Mark E Dudley
Francesco M Marincola
Frédéric Lévy
National Institutes of Health Clinical Center · USUniversity of Lausanne · CHNational Institutes of Health · US

Funding

Immunogenetics of Vaccine TherapyZIACL002115 · CLC · CLINICAL CENTER · PI MARINCOLA, FRANCESCO M · 2009 to 2010
$0k
Immunogenetics of Vaccine TherapyZ01CL002115 · CLC · CLINICAL CENTER · PI MARINCOLA, FRANCESCO M · 2003 to 2005
–
6 · The paper itself

Abstract

Immune responses against tumor-associated antigens rely on efficient epitope presentation. The melanoma-associated antigen (Ag) gp100 contains HLA-A*0201 ligands that are characterized by low to medium binding affinity, among which gp100(209-217) is the most prominent (Kawakami et al., J Immunol 154:3961-3968, 1995). While this epitope is a natural T-cell target, it primes with low-efficiency T-cell responses during immunization. A modified gp100 epitope, gp100(209-217T210M), that contains a Thr to Met substitution at position 2 of the antigenic nonamer is characterized by high binding affinity for HLA-A*0201 and elicits strong and clinically effective T-cell responses. This higher affinity is believed to represent the sole reason for enhanced immunogenicity. Contrasting with this observation is the unpredictable relationship between affinity and immunogenicity observed in other antigen systems. In addition, we noted a striking difference between the capability of endogenously processed gp100(209-217) and gp100(209-217T210M) to induce T-cell responses in an in vitro model. Therefore, we questioned whether factors other than HLA-affinity might play a role in determining the immunogenicity of these epitopes. In the present study, we evaluated the in vitro proteasomal cleavages of 23meric precursor peptides encompassing the native sequence (gp100(201-223)) or the modified sequence (gp100(201-223T210M)). Here we show that the standard proteasome liberates the C-termini of both antigenic peptides but not the N-termini. Quantitative analysis of the digestion products revealed that more of the fragments displaying the final C-termini were produced from the wild-type precursor. However, a stronger TCR engagement was observed when fractions of digested gp100(201-223T210M) were used to activate an HLA-A*0201-expressing target T-cell clone. This difference was also found using separately produced, synthetic nonamers. In conclusion, the high binding affinity of gp100(209-217T210M) seems to compensate for possible differences in proteasomal cleavage at the biological level. Since the final antigenic nonamer is not directly produced by the proteasome, additional further factors may influence the antigenic peptide availability, such as post-proteasomal processing and intracellular peptide transport.

Indexed as

Cells, CulturedChromatography, High Pressure LiquidCysteine EndopeptidasesEpitopes, T-LymphocyteErythrocytesgp100 Melanoma AntigenHLA-A2 AntigenHLA-A AntigensHumansLigandsMass SpectrometryMembrane GlycoproteinsMultienzyme ComplexesNeoplasm ProteinsPeptide FragmentsProteasome Endopeptidase ComplexCysteine EndopeptidasesEpitopes, T-Lymphocytegp100 Melanoma AntigenHLA-A*02:01 antigenHLA-A2 AntigenHLA-A AntigensLigandsMembrane GlycoproteinsMultienzyme ComplexesNeoplasm ProteinsPeptide FragmentsPMEL protein, humanProteasome Endopeptidase ComplexReceptors, Antigen, T-Cell

Identifiers

PMID15133631
PMCPMC11032984
OpenAlexW1992302390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.